New! View global litigation for patent families

DE69535195D1 - Substituierte imide als tnf inhibitoren - Google Patents

Substituierte imide als tnf inhibitoren

Info

Publication number
DE69535195D1
DE69535195D1 DE1995635195 DE69535195A DE69535195D1 DE 69535195 D1 DE69535195 D1 DE 69535195D1 DE 1995635195 DE1995635195 DE 1995635195 DE 69535195 A DE69535195 A DE 69535195A DE 69535195 D1 DE69535195 D1 DE 69535195D1
Authority
DE
Grant status
Grant
Patent type
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1995635195
Other languages
English (en)
Other versions
DE69535195T2 (de )
Inventor
George Muller
Mary Shire
I Stirling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
DE1995635195 1994-12-30 1995-11-20 Substituierte imide als tnf inhibitoren Expired - Lifetime DE69535195D1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08366679 US6429221B1 (en) 1994-12-30 1994-12-30 Substituted imides
PCT/US1995/015384 WO1996020926A1 (en) 1994-12-30 1995-11-20 Substituted imides as tnf inhibitors

Publications (1)

Publication Number Publication Date
DE69535195D1 true DE69535195D1 (de) 2006-10-05

Family

ID=23444039

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1995635195 Expired - Lifetime DE69535195T2 (de) 1994-12-30 1995-11-20 Substituierte imide als tnf inhibitoren
DE1995635195 Expired - Lifetime DE69535195D1 (de) 1994-12-30 1995-11-20 Substituierte imide als tnf inhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1995635195 Expired - Lifetime DE69535195T2 (de) 1994-12-30 1995-11-20 Substituierte imide als tnf inhibitoren

Country Status (11)

Country Link
US (3) US6429221B1 (de)
EP (1) EP0800514B1 (de)
JP (1) JP4118329B2 (de)
KR (1) KR20040007729A (de)
CA (1) CA2208671C (de)
DE (2) DE69535195T2 (de)
DK (1) DK0800514T3 (de)
ES (1) ES2271948T3 (de)
FI (1) FI972709A (de)
RU (1) RU2162078C2 (de)
WO (1) WO1996020926A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US6429212B1 (en) 1996-08-16 2002-08-06 Ishihara Sangyo Kaisha Ltd. Medicinal composition
EP0818439B1 (de) * 1996-07-02 1999-10-13 Nisshin Flour Milling Co., Ltd. Imid derivate
ES2315435T3 (es) * 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
EP0933360A1 (de) 1997-12-22 1999-08-04 Cancer Research Campaign Technology Limited Synthese von Beta-lactamen
ES2138561B1 (es) * 1998-04-17 2000-07-01 Univ Madrid Complutense Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
WO2002068414A8 (en) 2001-02-27 2010-02-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CA2444704C (en) * 2001-04-23 2012-07-10 University Of Virginia Patent Foundation Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
EP2087908A1 (de) 2001-06-26 2009-08-12 Amgen, Inc. Antikörper gegen opgl
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1668296A (zh) * 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
CA2501936A1 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
WO2004043336A3 (en) * 2002-11-06 2004-07-29 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
KR100923173B1 (ko) 2002-11-06 2009-10-22 셀진 코포레이션 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨억제 약물의 사용 방법 및 그 조성물
JP2006510617A (ja) * 2002-11-18 2006-03-30 セルジーン・コーポレーションCelgene Corporation (+)−3−(3,4−ジメトキシ−フェニル)−3−(1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−プロピオンアミドの使用方法およびそれを含む組成物
WO2004054501A3 (en) * 2002-11-18 2004-08-26 Celgene Corp Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US7173058B2 (en) 2002-12-30 2007-02-06 Celgene Corporation Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1663223B1 (de) 2003-09-17 2014-01-01 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Thalidomid-analoga als tnf-alpha-modulatoren
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
EP1692128A1 (de) 2003-11-19 2006-08-23 Signal Pharmaceuticals LLC Indazolverbindungen und verfahren zu deren anwendung als proteinkinaseinhibitoren
US7684506B2 (en) 2004-02-13 2010-03-23 Panasonic Corporation Transmitter apparatus, receiver apparatus, and wireless communication method
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
JP2007532642A (ja) * 2004-04-14 2007-11-15 セルジーン・コーポレーションCelgene Corporation 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
JP2007533760A (ja) * 2004-04-23 2007-11-22 セルジーン・コーポレーションCelgene Corporation 肺高血圧症を治療し管理するための、pde4モジュレーターの使用方法及びpde4モジュレーターを含む組成物
JP2008512378A (ja) * 2004-09-03 2008-04-24 セルジーン・コーポレーションCelgene Corporation 置換複素環式化合物及びその使用
KR20070085454A (ko) * 2004-10-28 2007-08-27 셀진 코포레이션 중추신경계 손상의 치료 및 관리를 위하여 pde4조절제를 사용하는 방법 및 조성물
EP2395995A1 (de) 2009-02-10 2011-12-21 Celgene Corporation Anwendungsverfahren und zusammensetzungen mit pde4-modulatoren zur behandlung, prävention und management von tuberkulose
CA2794096A1 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
JP2013531499A (ja) 2010-06-15 2013-08-08 セルジーン コーポレイション 乾癬の治療のためのバイオマーカー
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4215114A (en) * 1976-11-12 1980-07-29 The Upjohn Company Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
BE903541Q (fr) * 1984-10-30 1986-02-17 Kanegafuchi Chemical Ind Procede de fabrication d'un latex coagule de configuration spherique
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
DE69004837T2 (de) * 1989-03-22 1994-04-07 Bioresearch Spa Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH0625163A (ja) * 1992-07-03 1994-02-01 Ube Ind Ltd N−(ジメトキシベンジル)フタルイミド類およびその製造法
WO1994008976A1 (en) * 1992-10-08 1994-04-28 E.I. Du Pont De Nemours And Company Fungicidal and miticidal aminopyrimidines
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
JPH09506350A (ja) * 1993-11-30 1997-06-24 ジー.ディー.サール アンド カンパニー 炎症の治療のための置換ピラゾリルベンゼンスルホンアミド
US5674533A (en) * 1994-07-07 1997-10-07 Recordati, S.A., Chemical And Pharmaceutical Company Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
EP0925294B1 (de) 1996-07-24 2002-12-11 Celgene Corporation Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
ES2315435T3 (es) * 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US6395754B1 (en) 1997-05-30 2002-05-28 Celgene Corporation, Et Al. Substituted 2-(2,6-dioxopiperidin-3-yl)- phthalimides and 1-oxoisoindolines and method of reducing TNFα levels
CA2295295A1 (en) * 1997-07-31 1999-02-11 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing tnf.alpha. levels
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
EP1115405B1 (de) 1998-09-25 2007-05-16 A+ Science Invest AB Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
CN1342146A (zh) * 1999-03-18 2002-03-27 塞尔基因公司 取代的1-氧代-和1,3-二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof

Also Published As

Publication number Publication date Type
CA2208671A1 (en) 1996-07-11 application
KR20040007729A (ko) 2004-01-24 application
US20020143027A1 (en) 2002-10-03 application
DE69535195T2 (de) 2007-07-12 grant
US7329761B2 (en) 2008-02-12 grant
US20050090516A1 (en) 2005-04-28 application
ES2271948T3 (es) 2007-04-16 grant
EP0800514A1 (de) 1997-10-15 application
US6429221B1 (en) 2002-08-06 grant
RU2162078C2 (ru) 2001-01-20 grant
JPH10511946A (ja) 1998-11-17 application
DK0800514T3 (da) 2006-12-27 grant
FI972709D0 (de) grant
WO1996020926A1 (en) 1996-07-11 application
JP4118329B2 (ja) 2008-07-16 grant
CA2208671C (en) 2009-02-10 grant
FI972709A (fi) 1997-08-29 application
US6844359B2 (en) 2005-01-18 grant
EP0800514B1 (de) 2006-08-23 grant
FI972709A0 (fi) 1997-06-23 application

Similar Documents

Publication Publication Date Title
DE29612083U1 (de) Senkelektrantanordnung
DE29622549U1 (de) Aufwindkraftwerk
DE29600373U1 (de) Luftpolstertasche
DE29602184U1 (de) Zwangsgekühlter Schaltschrank
DE29616179U1 (de) Treibstangenumlenkschloß
DE29617261U1 (de) Bogenrotationsdruckmaschine
DE29603926U1 (de) Wasserentkeimungsgerät
DE29605083U1 (de) Müllgroßbehälter
DE29606408U1 (de) Radsicherungsbolzen
DE29606475U1 (de) Flachantenne
DE29615691U1 (de) Wandspreizdübel
DE29613310U1 (de) Bitumenbahn
DE29618798U1 (de) Gurtanlegehilfe
DE29620357U1 (de) Seitenüberwacher
DE29607073U1 (de) Gutaufnahmebehälter
DE29622647U1 (de) Hochtemperaturdämmsystem
DE29614257U1 (de) Lateralelement
DE29605583U1 (de) Mehrkantenski
DE29608842U1 (de) Behelfsvase
DE29610310U1 (de) Teebeutelausdrücker
DE29618745U1 (de) Antennensteckdose
DE29611749U1 (de) Distanzschraube
DE29610959U1 (de) Präsent
DE29613837U1 (de) Klemmnippelschraube
DE29615893U1 (de) Chipkartenlese- und Programmiergerät

Legal Events

Date Code Title Description
8364 No opposition during term of opposition